Regeneus has revised expected timing of an osteoarthritis (OA) clinical development licence deal for Progenza in Japan to Q4 CY18 (vs Q218); it is currently in active discussions with several parties. A licence deal would trigger a US$5m milestone payment from partner AGC and would effectively see Progenza commence a Phase II trial in knee OA in Japan. Regeneus is in separate discussions with potential licensees for other indications and territories for Progenza, as well as for its other pipe
04 Sep 2018
Regeneus - Several interested parties in Japan
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Regeneus - Several interested parties in Japan
Cambium Bio Ltd (CMB:ASX) | 0 0 -7.7% | Mkt Cap: 25.1m
- Published:
04 Sep 2018 -
Author:
Dr Dennis Hulme -
Pages:
3
Regeneus has revised expected timing of an osteoarthritis (OA) clinical development licence deal for Progenza in Japan to Q4 CY18 (vs Q218); it is currently in active discussions with several parties. A licence deal would trigger a US$5m milestone payment from partner AGC and would effectively see Progenza commence a Phase II trial in knee OA in Japan. Regeneus is in separate discussions with potential licensees for other indications and territories for Progenza, as well as for its other pipe